metapristone and Ovarian-Neoplasms

Recent global epidemiological studies revealed the lower ovarian cancer death from long-term use of oral contraceptives. However, the underlying mechanism of action is not clear. Here, we use the abortifacient metapristone (RU486 derivative) to test the hypothesis that the contraceptives might interrupt CXCL12/CXCR4 chemokine axis to inhibit ovarian cancer metastasis. Metapristone at concentrations (

Topics: Abortifacient Agents; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Chemoprevention; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Peritoneal Neoplasms; Peritoneum; Receptors, CXCR4; Signal Transduction